Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 8:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Vascular Death Clear all
Completed Phase 3 Interventional Results available

Cardiovascular Inflammation Reduction Trial

NCT01594333
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Methotrexate, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
4,786 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
404
States / cities
Birmingham, Alabama • Fort Payne, Alabama • Guntersville, Alabama + 296 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2020 · Synced Sep 23, 2026, 8:15 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure

NCT01877915
View directory record Official record
Conditions
Heart Failure, Coronary Artery Disease
Interventions
Rivaroxaban, Placebo, Standard of care for heart failure and coronary artery disease
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 95 Years
Enrollment
5,081 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
115
States / cities
Alexander City, Alabama • Birmingham, Alabama • Mobile, Alabama + 112 more
Source: ClinicalTrials.gov public record
Updated May 9, 2019 · Synced Sep 23, 2026, 8:15 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease

NCT01732822
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
Ticagrelor, Clopidogrel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
50 Years to 130 Years
Enrollment
13,885 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
290
States / cities
Alexander City, Alabama • Auburn, Alabama • Birmingham, Alabama + 239 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2017 · Synced Sep 23, 2026, 8:15 PM EDT
Recruiting No phase listed Observational

Tezspire Cardiac Events PASS

NCT06951867
View directory record Official record
Conditions
Cardiovascular Events, MACE
Interventions
Tezepelumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 130 Years
Enrollment
16,640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 23, 2026, 8:15 PM EDT
Active, not recruiting No phase listed Observational

International Spontaneous Coronary Artery Dissection (SCAD) "iSCAD" Registry

NCT04496687
View directory record Official record
Conditions
Spontaneous Coronary Artery Dissection
Interventions
Not listed
Lead sponsor
SCAD Alliance
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
30
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 23, 2026, 8:15 PM EDT
Active, not recruiting Phase 3 Interventional

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

NCT06383390
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
Interventions
Retatrutide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
205
States / cities
Alabaster, Alabama • Birmingham, Alabama • Daphne, Alabama + 159 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 23, 2026, 8:15 PM EDT
Recruiting Not applicable Interventional

Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors

NCT05643235
View directory record Official record
Conditions
Atrial Fibrillation, Supraventricular Arrhythmia, Ventricular Arrhythmias and Cardiac Arrest, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Interventions
Medtronic LINQ-2 Insertable Cardiac Monitor (ILR)
Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Sep 23, 2026, 8:15 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Examining the Long-Term Risks of Oophorectomy

NCT00655447
View directory record Official record
Conditions
Coronary Heart Disease, Stroke, Breast Cancer, Ovarian Cancer, Cancer, Hip Fracture, Death
Interventions
Not listed
Lead sponsor
Parker, William H., M.D.
Other
Eligibility
30 Years to 55 Years · Female only
Enrollment
32,175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1980 – 2004
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2008 · Synced Sep 23, 2026, 8:15 PM EDT
Completed Not applicable Interventional

Multidisciplinary Inpatient Palliative Care Intervention

NCT00325611
View directory record Official record
Conditions
Cerebrovascular Accident, Cancer, Coronary Arteriosclerosis, Heart Failure, Congestive, Diabetes Mellitus, Acquired Immunodeficiency Syndrome, Failure to Thrive, Pulmonary Disease, Chronic Obstructive, Dementia, Kidney Failure, Chronic, Pneumonia, Liver Failure, Renal Failure, Respiratory Failure, Stroke
Interventions
Multidisciplinary palliative care team met with patient
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 14, 2006 · Synced Sep 23, 2026, 8:15 PM EDT
Active, not recruiting Phase 2 Interventional

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

NCT06449222
View directory record Official record
Conditions
Locally Advanced Breast Cancer, Triple Negative Breast Cancer, Metastatic Triple Negative Breast Cancers
Interventions
BNT327 Dose Level 1 (DL1), BNT327 Dose Level 1 (DL2), Nab-placlitaxel, Carboplatin, Gemcitabine, Paclitaxel, Eribulin, BNT327 Optimized Dose, BNT327 Equivalent Q3W Dose
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
13
States / cities
Beverly Hills, California • Los Angeles, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 23, 2026, 8:15 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)

NCT03797326
View directory record Official record
Conditions
Advanced Solid Tumors, Triple Negative Breast Cancer, Ovarian Cancer, Gastric Cancer, Colorectal Cancer, Glioblastoma, Biliary Tract Cancers, Pancreatic Cancer
Interventions
Pembrolizumab, Lenvatinib
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
611 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
14
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 23, 2026, 8:15 PM EDT
Recruiting Phase 2 Interventional

Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)

NCT06698250
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Zanzalintinib, Durvalumab, Tremelimumab
Drug
Lead sponsor
Anwaar Saeed
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Pittsburgh, Pennsylvania • Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Sep 23, 2026, 8:15 PM EDT
Not listed No phase listed Observational

Characterization and Prediction of Atrial Fibrillation-caused Adverse Events After Hospital Discharge for Cardiac Surgery

NCT03466125
View directory record Official record
Conditions
Atrial Fibrillation, Stroke, Acute, Death
Interventions
Cardiac surgery
Procedure
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
20 Years to 99 Years
Enrollment
25,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Sep 23, 2026, 8:15 PM EDT
Completed Phase 1 Interventional

A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)

NCT02431208
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Daratumumab, Lenalidomide, Pomalidomide, Dexamethasone
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
31
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Sep 23, 2026, 8:15 PM EDT
Terminated Not applicable Interventional Results available

DEfibrillators To REduce Risk by MagnetIc ResoNance Imaging Evaluation

NCT00487279
View directory record Official record
Conditions
Coronary Artery Disease, Left Ventricular Dysfunction, Sudden Cardiac Death
Interventions
Defibrillator, Control
Device · Other
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
56
States / cities
Anchorage, Alaska • Tucson, Arizona • Glendale, California + 42 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Sep 23, 2026, 8:15 PM EDT
Terminated No phase listed Observational

Genotype Guided Comparison of Clopidogrel and Prasugrel Outcomes Study

NCT00995514
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Not listed
Lead sponsor
Medco Health Solutions, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
4,471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Franklin Lakes, New Jersey
Source: ClinicalTrials.gov public record
Updated May 29, 2012 · Synced Sep 23, 2026, 8:15 PM EDT
Completed Phase 3 Interventional

Efficacy of Implantable Defibrillator Therapy After a Myocardial Infarction

NCT00673842
View directory record Official record
Conditions
Myocardial Infarction, Sudden Death
Interventions
Implantable Cardioverter Defibrillator + Usual Care, Usual care
Device · Other
Lead sponsor
University of Calgary
Other
Eligibility
18 Years to 80 Years
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
29
States / cities
Huntsville, Alabama • Lakewood, Colorado • Tampa, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Sep 23, 2026, 8:15 PM EDT
Completed No phase listed Observational

Long-term Outcomes of Patients After Coronary Bifurcation Stenting

NCT00325884
View directory record Official record
Conditions
Coronary Artery Disease, Death, Myocardial Infarction
Interventions
Not listed
Lead sponsor
VA Boston Healthcare System
Federal
Eligibility
18 Years to 90 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
West Roxbury, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Sep 23, 2026, 8:15 PM EDT
Active, not recruiting Not applicable Interventional

The TRIABETES - ARMMS-T2D Study: A Randomized Trial to Compare Surgical and Medical Treatments for Type 2 Diabetes

NCT01047735
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Obesity
Interventions
Roux-en-Y Gastric Bypass Surgery, Laparoscopic Adjustable Gastric Banding, Lifestyle Weight Loss Intervention
Procedure · Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
25 Years to 55 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 23, 2026, 8:15 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer

NCT07079631
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
BNT314, Pumitamig, SoC chemotherapy treatment 1, SoC chemotherapy treatment 2, Bevacizumab
Biological · Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
482 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
4
States / cities
New Haven, Connecticut • Grand Rapids, Michigan • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 23, 2026, 8:15 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer

NCT06892548
View directory record Official record
Conditions
Advanced Lung Cancer
Interventions
BNT324, BNT327
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
594 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
17
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 23, 2026, 8:15 PM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Rapid Reversal of CNS-Depressant Drug Effect Prior to Brain Death Determination

NCT03743805
View directory record Official record
Conditions
Brain Death, Anoxic Brain Injury, Cardiac Arrest, Sedative Intoxication, Narcotic Intoxication
Interventions
Flumazenil, Naloxone
Drug
Lead sponsor
Prisma Health-Midlands
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Sep 23, 2026, 8:15 PM EDT
Completed Phase 3 Interventional Results available

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

NCT01327846
View directory record Official record
Conditions
Atherosclerosis
Interventions
Canakinumab, Placebo, Standard of care
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
10,066 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
315
States / cities
Athens, Alabama • Birmingham, Alabama • Fairhope, Alabama + 248 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Sep 23, 2026, 8:15 PM EDT
Active, not recruiting Phase 2 Interventional

Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy

NCT06449209
View directory record Official record
Conditions
Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer
Interventions
BNT327 Dose Level 1 (DL1), BNT327 Dose Level 2 (DL2), Etoposide, Carboplatin, Paclitaxel, Topotecan
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
18
States / cities
Anchorage, Alaska • Los Angeles, California • Clermont, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 23, 2026, 8:15 PM EDT